Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04818827 · ClinicalTrials.gov registry record

Ketamine Infusion as Sedative Analgesic in Severe ARDS

A clinical trial of Delirium and Mechanical Ventilation Complication, sponsored by Interfaith Medical Center.

Completed
Registry status
124
Enrollment target
1
Study location

NCT04818827: Completed study of Delirium and Mechanical Ventilation Complication, sponsored by Interfaith Medical Center.

NCT04818827 is a study of Delirium and Mechanical Ventilation Complication that has completed, run by Interfaith Medical Center. The registered enrollment target is 124 participants, below the 886-participant average among 62 other Delirium trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04818827, a study of Delirium and Mechanical Ventilation Complication, has completed, sponsored by Interfaith Medical Center.

COMPLETED
Registry status
124 participants
Enrollment target
1
Study location

Study Summary

To evaluate whether ketamine is a safe sedative-analgesic agent to be used in an intensive care unit (ICU) setting as compared to traditionally used agents such as propofol, opioids, and midazolam

Primary Outcome

The two groups were compared for all-cause mortality during the ICU stay

Study Locations (1)

New York

  • Interfaith Medical Center - New York

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2020-02-01
Est. Completion 2021-02-14
Interfaith Medical Center

1 total trials

What the finished NCT04818827 record still lists

NCT04818827 is an observational study that tracks outcomes without assigning an intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 886-participant average among 62 other Delirium trials with a reported enrollment target (86% lower).

The record links to 4 conditions, with Delirium appearing as the primary indexed condition, and to 0 interventions.

NCT04818827 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04818827 about?

NCT04818827 is a clinical study titled "Ketamine Infusion as Sedative Analgesic in Severe ARDS". To evaluate whether ketamine is a safe sedative-analgesic agent to be used in an intensive care unit (ICU) setting as compared to traditionally used agents such as propofol, opioids, and midazolam

What is the current status of trial NCT04818827?

This trial is currently completed. The enrollment target is 124 participants. The study started on 2020-02-01. Estimated completion is 2021-02-14.

What conditions does trial NCT04818827 study?

This clinical trial studies the following conditions: Delirium, Mechanical Ventilation Complication, Intensive Care Unit Syndrome, Sedatives and Hypnotics Causing Adverse Effects in Therapeutic Use.

Who is sponsoring clinical trial NCT04818827?

This trial is sponsored by Interfaith Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04818827 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Delirium

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04818827's enrollment target sits among peer trials

124 34th of 62 higher than 29 of 62 other Delirium trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Delirium trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04818827, the US trial registry maintained by the National Library of Medicine. NCT04818827 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.